Generics supplier Olon SpA, an Active Pharmaceutical Ingredients (API) contract development and manufacturing organisation (CDMO
), reported on Friday that it has completed the acquisition of the chemical division of the contract research (CRO) and CDMO
in Concord, Ohio, USA for an undisclosed value .
Recipharm is a CDMO
(Contract Development and Manufacturing Organisation) in the pharmaceutical industry, offering manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material including API and pharmaceutical product development.
Because serialization requires a high-level of investment, it is essential that the CDMO
be adequately invested in programs, technology and expertise.
Many of these new products have orphan drug status and as a CDMO
, we need to respond with a quick and seamless production route to market.
has a network of facilities primarily in North America and Europe, and approximately 9,000 professionals worldwide.
So, no, I don't have any firm answers when I'm asked how the new administration will impact the CDMO
sector, but I'll be doing my best to represent our member companies and make sure our lawmakers understand the ramifications of their actions on the companies that help bring safe, cost-effective medicines to the public.
Juraj Kuban also joins the CDMO
in the role of project development manager.
Know exactly what your company needs and what you're looking for in a CDMO
28 March 2017 - US-based Global Health Care Group has agreed to acquire US-based pharmaceutical and medical device CDMO
Lyophilization Services of New England, Inc.
technology will be used to produce enteric coated pellets aimed at preventing dissolution in the stomach, while allowing dissolution in the small intestine.
Recipharm is a CDMO
(Contract Development and Manufacturing Organisation) in the pharmaceutical industry offering manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material including API and pharmaceutical product development.
It also explains what a pharmaceutical company should expect from its CDMO
in the run-up to the regulatory changes.